Microbot Medical

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Braintree, MA.

Cue Health

Cassava Sciences Inc

Health care stocks worth knowing as the Omicron Covid-19 variant sweeps the globe.

Best Health Care Stocks To Buy Now? 3 For Your 2022 Watchlist

Microbot Medical Inc (NASDAQ: MBOT) is trading lower Tuesday as the stock pulls back following Monday's strength. Microbot Medical shares surged Monday after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.

Why Microbot Medical Shares Are Sliding Today

Microbot Medical is catching investors' attention on Monday, with shares up more than 70% at one point during the day. Here's why.

MBOT Stock Alert: Why Is Microbot Soaring 50% Today?

Microbot Medical Inc (NASDAQ: MBOT) is soaring Monday morning after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications. Microbot Medical will continue to develop the LIBERTY Robotic System independently for use in peripheral and coronary procedures.

Why Microbot Medical Shares Are Soaring Today

The stock price of Microbot Medical Inc (NASDAQ: MBOT) increased by over 50% pre-market today. This is why it happened.

Microbot Medical Stock (MBOT): Why The Price Surged Today

HINGHAM, Mass., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker's Neurovascular division to integrate its neurovascular instruments with Microbot's LIBERTY Robotic System to develop the world's first dedicated robotic procedural kits for use in certain neurovascular procedures.

Microbot Medical Announces Strategic Collaboration with Stryker Corporation to Develop the LIBERTY® Robotic System for Neurovascular Applications

HINGHAM, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a third patent application covering the Company's LIBERTY® Robotic System. The Company has secured all three U.S. patents during 2021. Globally, the Company now has 47 patents issued/allowed and 26 pending patent applications and is continuously submitting applications to protect its Intellectual Property.

Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States; Success of Protecting Novel Intellectual Property Complements Recent Design Freeze Achievement

HINGHAM, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY® Robotic System for commercialization. In conjunction with recently announced design freeze, Dr. Eyal Morag, Microbot's Chief Medical Officer, traveled to the United States to establish a clinical infrastructure with multiple sites and leading physicians for the commencement of a human clinical trial, which is expected to commence in the second half of 2022.

Microbot Medical Initiates Search for U.S. Clinical Sites for the LIBERTY® Robotic System

Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA

Microbot Medical Achieves Design Freeze of the LIBERTY® Robotic System; Meets Previously Stated Milestone Timeline

HINGHAM, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent application covering the Company's LIBERTY® Robotic System. Globally, the Company now has 46 patents issued/allowed and 24 pending patent applications and is continuously submitting applications to protect its Intellectual Property.

Microbot Medical Secures Additional Patent for the LIBERTY® Robotic System in the United States

HINGHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance covering the Company's LIBERTY® Robotic System. Globally, the Company now has 45 patents issued/allowed and 24 pending patent applications.

Microbot Medical Secures Patent for LIBERTY® Robotic System in the United States

HINGHAM, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that China has become the latest global jurisdiction to issue a Notice of Allowance (NOA) for the Company's innovative ‘One & Done' guidewire technology, joining the European Union along with those received earlier this year from Japan and Israel. Globally, the Company now holds a total of 44 patents issued/allowed and 24 pending patent applications.

Microbot Medical Secures Patent Allowance in China; Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done' Technology

HINGHAM, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Company's Scientific Advisory Board (SAB). Dr. Weisz is a practicing interventional cardiologist and clinical researcher who has pioneered novel robotic-enhanced coronary interventions, as well as navigation and positioning technologies. His areas of expertise include cardiac catheterization, coronary artery disease and diagnostic angiography, which make his assistance an invaluable asset to Microbot as it continues to develop the LIBERTY™ Robotic System.

Leading Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical's Scientific Advisory Board

HINGHAM, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Global patent jurisdictions continue to recognize Microbot Medical Inc.'s (Nasdaq: MBOT) innovative ‘One & Done' guidewire technology, as the Israel Intellectual Property Office has issued a Notice of Allowance (NOA). The allowed application covers Microbot's double guidewire technology that has been granted in Europe, Japan and now Israel. Globally, Microbot Medical holds a total of 42 patents issued/allowed and 23 pending patent applications.

Microbot Medical Secures Additional Protection for the One & Done Guidewire Technology with another Notice of Patent Allowance

Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders

Microbot Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists

Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events

Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System

HINGHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, CEO, President and Chief Executive Officer, will be presenting virtually at two upcoming investor conferences. Mr. Gadot will review the Company's recent achievements, current progress and expected 2021 milestones.

Microbot Medical to Share Current Progress and Expected 2021 Milestones at Upcoming Conferences

HINGHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has received patents in multiple jurisdictions, further demonstrating the Company's continued execution of expanding and protecting its Intellectual Property (IP) portfolio. The Company now has 40 issued/allowed patents and 23 patent applications pending worldwide.

Microbot Medical Secures Patents in Multiple Global Jurisdictions

Webcast to be Held on Thursday November 12 th at 2:00pm ET

Microbot Medical to Highlight Progress and Recent Achievements at H.C. Wainwright 6th Annual Israel Conference

HINGHAM, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 15/592,227, which pertains to a device for reducing dialysis shunt stenosis. The allowed patent application is a Continuation of Patent No. 9,675,748, which was issued on June 13, 2017.

Microbot Medical Receives Notice of Allowance for U.S. Patent Covering a System for Reducing Dialysis Shunt Stenosis

Webinar to be Held on Wednesday August 26th at 11am ET Webinar to be Held on Wednesday August 26th at 11am ET

Microbot Medical Schedules Virtual Meeting to Address Increased Interest Following its Recent Announcement  

World’s First Fully Disposable Surgical Robot Achieved all Endpoints with No Intraoperative Adverse Events

Microbot Medical Announces Successful Animal Study Utilizing Its LIBERTY™ Robotic System

Results to be shared on August 17th during Needham’s Virtual Med Tech & Diagnostics Conference Results to be shared on August 17th during Needham’s Virtual Med Tech & Diagnostics Conference

Microbot Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic System

Vascular Interventions Executive Will Contribute Significantly to the Development and Commercialization of LIBERTY Robotic System Vascular Interventions Executive Will Contribute Significantly to the Development and Commercialization of LIBERTY Robotic System

Microbot Medical Appoints the Co-Founder of Corindus Vascular Robotics to its Board of Directors

Microbot: Miniature Medical Device Company Can Be Successful

News for Microbot Medical Stock (MBOT)